Sofinnova Crossover I SLP Plans to Sell 1.2 Million ADS of Abivax S.A.

Sofinnova Crossover I SLP, an affiliate of Abivax S.A., has filed a Form 144 with the SEC indicating its intention to sell 1.2 million American Depositary Shares (ADS) of Abivax S.A. The shares were acquired during the company's IPO on October 20, 2023. The sale is planned to occur around October 28, 2025, with an aggregate market value of approximately $111.3 million. The securities are listed on NASDAQ, and the transaction will be facilitated by Leerink Partners. Sofinnova Crossover I SLP has reported no securities sold in the past three months. The filing was signed by Christophe Blanche on October 28, 2025.